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Fragile X-associated primary ovarian insufficiency (FXPOI) is among the family of disorders caused by the expansion
of a CGG repeat sequence in the 5' untranslated region of the X-linked gene FMR1. About 20% of women who carry
the premutation allele (55 to 200 unmethylated CGG repeats) develop hypergonadotropic hypogonadism and cease
menstruating before age 40. Some proportion of those who are still cycling show hormonal profiles indicative of
ovarian dysfunction. FXPOI leads to subfertility and an increased risk of medical conditions associated with early
estrogen deficiency. Little progress has been made in understanding the etiology of this clinically significant
disorder. Understanding the molecular mechanisms of FXPOI requires a detailed knowledge of ovarian FMR1 mRNA
and FMRP’s function. In humans, non-invasive methods to discriminate the mechanisms of the premutation on
ovarian function are not available, thus necessitating the development of model systems. Vertebrate (mouse and
rat) and invertebrate (Drosophila melanogaster) animal studies for the FMR1 premutation and ovarian function exist
and have been instrumental in advancing our understanding of the disease phenotype. For example, rodent
models have shown that FMRP is highly expressed in oocytes where it is important for folliculogenesis. The two
premutation mouse models studied to date show evidence of ovarian dysfunction and, together, suggest that the
long repeat in the transcript itself may have some pathological effect quite apart from any effect of the toxic
protein. Further, ovarian morphology in young animals appears normal and the primordial follicle pool size does
not differ from that of wild-type animals. However, there is a progressive premature decline in the levels of most
follicle classes. Observations also include granulosa cell abnormalities and altered gene expression patterns. Further
comparisons of these models are now needed to gain insight into the etiology of the ovarian dysfunction.
Premutation model systems in non-human primates and those based on induced pluripotent stem cells show
particular promise and will complement current models. Here, we review the characterization of the current models
and describe the development and potential of the new models. Finally, we will discuss some of the molecular
mechanisms that might be responsible for FXPOI.
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Fragile X-associated primary ovarian insufficiency (FXPOI)
is among the family of disorders caused by the expansion
of a CGG repeat sequence located in the 5' untranslated re-
gion (UTR) of the X-linked gene FMR1. About 20% of
women who carry an allele with 55 to 200 unmethylated
CGG repeats, called the premutation (PM) allele, develop
hypergonadotropic hypogonadism and cease menstruating
before age 40, a condition also known as premature ovar-
ian failure (POF). The 20% contrasts with a rate of about
1% of the general population (for reviews, see [1-3]).
The term primary ovarian insufficiency (POI) encom-
passes both POF and occult indicators of ovarian function
such as decreased levels of the anti-Müllerian hormone
and increased levels of the follicle-stimulating hormone.
As this entire spectrum, including the altered hormone
profile is observed among women with the PM [4-9], the
term ‘FXPOI’ is well suited [10]. Importantly, the propor-
tion of women with the PM who manifest occult hormone
indicators or clinical signs of ovarian dysfunction is un-
known, as is the extent to which such indicators predict
infertility or POF. This is a clinically significant gap as
women with FXPOI can still become pregnant and may
have a child with fragile X syndrome [11].
FXPOI is clinically significant. The most immediate and
significant consequence of diminished ovarian function is
reduced fertility [12,13]. The state of early estrogen defi-
ciency leads to additional clinical consequences such as an
increased risk of low bone density, earlier onset osteopor-
osis and bone fractures [14], impaired endothelial function
[15], earlier onset of coronary heart disease [16], and in-
creased cardiovascular mortality and overall mortality
(e.g., [17,18]). In addition, women who have an early meno-
pause are reported to suffer from more anxiety, depression,
somatization, sensitivity, hostility and psychological distress
than women with normal ovarian function [19].
We know very little about the mechanisms leading to
FXPOI. It is well established that full mutation carriers,
or those with an allele of >200 methylated repeats that
leads to silencing of FMR1, do not suffer from ovarian
dysfunction. Thus, the significant reduction of the FMR1
protein product, FMRP, does not appear to be the culprit.
There are important molecular attributes of the PM: with
increasing repeat length, there are increasing FMR1
transcript levels and decreasing FMRP levels [20-24].
As discussed in more detail below, many researchers have
postulated that FMR1 mRNA gain-of-function toxicity
may underlie FXPOI, as is the case for the other PM-
associated disorder, fragile X-associated tremor/ataxia syn-
drome (FXTAS) [25].
Not all women with the PM suffer from POF or occult
indicators of ovarian dysfunction. Four factors have been
investigated to explain the incomplete penetrance of POF
among PM carriers: repeat length, skewed X-chromosomeinactivation (XCI), background genes and smoking. First,
there is a strong non-linear association between the pe-
netrance of POF and repeat number. Women with mid-
range PM repeats (approximately 70 to 90 repeats) have
the highest risk for POF. Carriers of both smaller and lar-
ger PM repeat lengths also have an increased risk of POF
compared to the general population, but not to the same
extent as mid-range repeat carriers [7,13,26-28]. Second,
skewed XCI may play a role in modifying the risk or sever-
ity of FXPOI, as FMR1 is located on the X chromosome.
However, no study has found evidence for skewed XCI
based on samples from fresh blood among PM carriers
with FXPOI [5,7,28-31]. Assuming that XCI in blood can
be used as a proxy for the correct target tissue, one pos-
sible explanation for this observation is that the toxic ef-
fect of the PM acts during a stage in development when
both X chromosomes are active. Third, studies have
shown that the risk of POF depends not only on the PM
allele, but also on other background genes [27,32]. Finally,
smoking, a known risk factor for reducing the age at me-
nopause, has been shown to have the same effect on wo-
men with the PM as it does on non-carriers [13,27].
In short, little is known about the etiology of FXPOI
and the cause of its reduced penetrance and variable ex-
pressivity. The development and use of model systems
to uncover the associated mechanism has just begun.
The overall goal of this review is to describe these model
systems and the initial steps taken to elucidate the me-
chanisms underlying the association between the FMR1
PM and ovarian function. We will begin with a descrip-
tion of the current rodent model systems, which are the
most mature in terms of their characterization of the ef-
fect of the PM. We will then describe new models that
have the potential to advance the field.
Rodent model systems: recapitulation of FXPOI
Only recently have FMR1 mutation murine models been
used to study ovarian function (Table 1). Published re-
sults for two PM mouse models [33,34] and unpublished
studies for another (RKH et al., unpublished), indicate
their value in studying the etiology for FXPOI. A full
mutation mouse model further implicates FMR1 as hav-
ing an important role in folliculogenesis [35]. Finally, the
characterization of expression patterns of FMR1 in the
ovary of the rat shows the potential of this model in un-
derstanding the toxic effect of the PM [36]. Here we will
review these models with respect to their ovarian pheno-
type to underscore their importance in future research
on FXPOI.
Model construction
The construction of each model has been reported in
detail previously. Dr Usdin’s team originally constructed
a knock-in (KI) murine model to study instability of the
Table 1 Comparison of FMR1-related ovarian phenotypes among rodent model systems
CGGnih [33] YAC-TG296 [34] CGGdut [40] Full mutation/knockout [35] Rat [36]
Genetic background C57BL/6 FVB/N C57BL/6 and FVB/n FVB129P2 Sprague–Dawley
Premutation repeat size Approximately 130 repeats (variable) (CGG)9AGG(CGG)9AGG(CGG)72 >100 repeats (variable) n/a n/a
Expression of WT FMRP expression: FMRP expression: FMRP expression: n/a FMRP expression:
• In GCs, LCs • In GCs and oocytes at all
follicle stages
• In GCs of growing
follicles (20 weeks)
• In GCs, TCs, stroma of
pre-antral follicles
• In oocytes of all ages (high in primordial,
primary and early pre-antral follicles) • Not in interstitial cells • LCs in older stages• In oocytes
• Not in interstitial cells
FMR1 mRNA expression:
• In oocyte cytoplasm in
primordial follicles (only
observed in nucleus in a
small fraction of cells)
• In GCs and oocytes at all
follicle stages
• Higher levels in ovaries compared with brain
• Not in stromal cells• Not in interstitial cells
• Weaker in atretic cells
• Levels increased with
increasing stage of follicular
development
FMR1 mRNA expression:
• Pre-antral and early antral
follicles had higher expres
sion than pre-ovulatory
follicles
FMRP levels in model • Reduced FMRP in GCs and LCs No altered expression
measured at 6 to 8 weeks
43% reduced in ovaries
at 40 weeks
n/a
• At 7 months, no altered levels in any ovarian
cell
• At 7 months, abnormal distribution, higher in
nucleus than cytoplasm
FMR1 mRNA levels in
model
• Increased at all ages in ovary Increased levels in ovaries Increased in ovaries by
4.8-fold at 40 weeks• Increased in GCs and oocytes (7 months)
Nuclear inclusions • One seen in 1 oocyte of 1/45 PM mice Not done None
• None observed in other ovarian cells
Ubiquitination • Higher levels in oocytes Not done
• Animals with > FMRP nuclear distribution had
highest number of oocytes with high
concentration of ubiquitination
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Table 1 Comparison of FMR1-related ovarian phenotypes among rodent model systems (Continued)
Histopathology • Grossly normal at 4 months, but 15% smaller • Reduced uterine weight • Increased number of follicles
by 3 weeks
• Ovarian volume did not change from 4 to 12
months; no correlation with total number of
oocytes and corpus lutea (in WT, declined
linearly and strong correlation)
• At PD8 and PD25, ovary size
did not differ
• Smaller size at 9 and 16
weeks
• Ovaries larger by 3 weeks
(by 12 and 18 weeks 22%
and 72% larger by mass
than controls)
• Interstitial hypertrophy and tubulostromal
hypertrophy (7 to 12 months) • Prominent cysts consistent
with corpus lutea
development at 18 weeks• Increase in ovarian cysts (incidence, number
and size)
Pattern of follicle counts
compared with WT
• Same at 4 months • At PD25, same number of
primordial follicles• >4 months, fewer follicles
• Number of mature follicles
reduced at PD25 and 9 weeks
• All subclasses of follicles were reduced
• Size of primordial pool correlated with
number of advancing subclasses • Reduction of less mature
follicle stages but not
significant
Corpus luteum
characteristics
• Reduced • Reduced at 9 weeks
• Decline associated with number of advanced
follicles
Granulosa cell
characteristics
• Antral follicles had 15% fewer GCs • Appeared with detached GC
layer
• Corona of mature follicles was partial or
missing leading to premature meiotic
progression
Atresia characteristics • High ratio of atretic follicles to advancing
follicles irrespective of estrus cycle
• Strong positive TUNEL in
follicles at PD35 to 22 weeks
showing an increased
number of atretic cells• Association of atresia rate and repeat number
Fertility characteristic • Not published, but unpublished work from
same group supports a lower fecundity.
• Increased sterility
• Delayed time to first
pregnancy
• Reduced number of pups per
litter
Hormone profile Not done • At 10 to 12 weeks, higher
levels of 17β-E2, but similar
levels at 16 and 22 weeks
• From 9 to 22 weeks, follicle-
stimulating hormone higher
and LH lower
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Table 1 Comparison of FMR1-related ovarian phenotypes among rodent model systems (Continued)
Expression of other
genes
Not done • At PD25, 8 and 14 weeks, LH
receptor downregulated
• Increased protein levels of
Tsc2, Sash1 and mTOR
• Large number of LH-induced
ovulation-related genes
downregulated at proestrus
stage in adults
• Reduced phosphorylated Akt
and phosphorylated mTOR,
but total levels of Akt and
mTOR were not altered
• No alterations in other major
known regulators of
folliculogenesis
GC, granulosa cell; LC, luteal cell; LH, luteinizing hormone; n/a, not applicable; PD, postnatal days; PM, premutation; WT, wild type; TC, theca cells; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling;
Akt, also known as Protein Kinase B (PKB), is a serine/threonine-specific protein kinase; mTOR, mammalian target of rapamycin.
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in the PM model was generated by serial ligation of short,
stable CGG · CCG-repeat tracts, which were then used to
replace the endogenous shorter murine repeat tract by
homologous recombination. The KI allele had only min-
imal differences from the wild-type (WT) murine Fmr1
gene in the region flanking the repeat. Therefore, females
have a normal mouse Fmr1 allele, and an Fmr1 allele that
is almost exactly the same as the endogenous mouse allele
except for the length of the repeat tract. These mice are in
a C57BL/6 background. This model will be referred to as
CGGnih.
Lu et al. used a transgenic model that carries a YAC
with the human PM allele that includes 90 repeats [34].
The line used (YAC-TG296) includes one copy of the
YAC and about 5 kb of flanking sequence and was bred
to WT FVB mice for five generations [38]. These mice
are homozygous for the WT Fmr1 allele. This line and
several others have been used to study repeat instability
[38] and the overexpression of FMRP [39].
Dr Willemsen’s team characterized their previously con-
structed KI mouse with an expanded CGG repeat in the
PM range (CGGdut). This KI mouse model was developed
by substituting the endogenous mouse 5' UTR containing
the CGG repeat with the corresponding region from a hu-
man allele carrying 98 CGG repeats [40]. These mice are
homozygous for the KI allele and have no WT Fmr1 allele.
They are on a mixed C57BL/6 and FVB/n genetic back-
ground. This model shows instability upon transmission
[41] and the biochemical, phenotypic and neuropatho-
logical characteristics of FXTAS [42]. At this time, this
model provides information about FMR1 expression in
ovarian tissues. Further work on the ovarian phenotype is
currently being conducted.
The role of FMRP in ovarian function has also been
examined in two other rodent models. Ovarian function
in a mouse model for the fragile X full mutation con-
taining a targeted disruption of the Fmr1 gene [43] has
recently been described [34]. The expression of FMRP
and Fmr1 during folliculogenesis has recently been eval-
uated in Sprague-Dawley rats [36].
Premutation leads to altered FMR1 expression levels
In all WT animals, FMRP has been identified in granulosa
cells (GCs), luteal cells and most prominently in oocytes.
In oocytes, expression was seen at all stages of folliculo-
genesis and primarily in the cytoplasm [33,36]. Expression
was not observed in the interstitial cells. For the rat
model, Ferder et al. [36] found that there were changes in
Fmr1 expression during follicle maturation, both at the
protein and mRNA levels. FMRP levels increased with in-
creasing follicle development. Fmr1 transcript levels were
similar in pre-antral and early antral follicles, but de-
creased in pre-ovulatory follicles. The authors suggestedthat Fmr1 expression in the ovary may be regulated at dif-
ferent levels and these may be independently controlled.
In addition, they found expression of at least four different
isoforms of FMRP during all stages of follicular growth.
These expression patterns differ from those observed in
the brain and testis.
Increased expression of Fmr1 mRNA in the ovary has
been seen in all PM mouse models. Interestingly, in the
CGGnih and WT littermates, there was a non-linear age
effect, where total ovary mRNA levels were higher at 12
months compared with 6 and 18 months of age. At 7
months, in situ hybridization studies of the CGGnih
model showed mRNA levels to be increased in oocytes
and GCs.
The expectation for relative FMRP levels differs among
the PM mouse models due to their construction. No dif-
ferences in FMRP levels between YAC-TG296 mice and
their WT littermates were found, when measured at 6 to
8 weeks. At 1 to 2 months, the CGGnih mice showed
relatively reduced levels of FMRP in GCs and luteal cells.
In the CGGdut PM model, a reduction in FMRP expres-
sion was noted at 2 months. This observed decrease is
similar to that found in the brain of these PM models
[37,41]. Again, the relative Fmr1 PM levels seemed more
pronounced in ovaries than in the brain for both the
CGGnih and the CGGdut models.
Interestingly, an abnormal distribution of FMRP when
measured at 7 months has been observed in the CGGnih
model: FMRP was more highly expressed in the nucleus
of oocytes than in the cytoplasm. There were eight times
as many oocytes with higher nuclear expression in the
PM model compared with the WT.
Two phenomena considered to be a consequence of
altered FMR1 expression in the brain were measured for
the CGGnih model: the presence of inclusion bodies and
ubiquitination. Essentially no inclusions were noted in
the ovarian cells of the PM or WT mice. With respect
to ubiquitination, ubiquitin in WT mice was distributed
throughout the cytoplasm and nucleoplasm. The CGGnih
mice showed higher levels of ubiquitin in oocytes, more
oocytes with elevated ubiquitin and a pronounced nu-
clear/perinuclear concentration than WT mice. Also,
those with the highest number of oocytes with nuclear
FMRP had the highest number of oocytes with high con-
centrations of ubiquitin.
Morphology of the premutation ovary
Both the CGGnih and YAC-TG296 models had smaller
ovaries by 4 months of age compared with WT mice, but
they were grossly normal. However, in the CGGnih model
from 4 to 12 months, there was no decrease in size, as
would be expected with the normal decrease in the num-
ber of oocytes and corpus lutea. This might be explained
by the noted interstitial hypertrophy and tubulostromal
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ies also had more and larger non-functional ovarian cysts.
Premutation leads to a depletion of follicles in later stages
of maturation
Examination of the pattern of follicle counts at all stages
provides insight into the effect of the PM. The total num-
ber of primordial follicles was comparable to WT mea-
sured at PD25 (YAC-TG296) and at 4 months (CGGnih).
This suggests that the establishment of the primordial
pool is not affected in PM mice. At PD25 and 9 weeks in
the YAC-TG296 model, the number of later subclasses of
follicles was reduced, and significantly so for mature folli-
cles, compared with WT mice. At ages over 4 months, the
CGGnih mice had a significant reduction of all subclasses
of follicles, with the size of the primordial pool being cor-
related to the number of advancing subclasses. Also, the
number of corpus lutea, the bodies that result from post-
ovulatory follicles, was reduced in PM mice compared
with WT mice. Together, these observations suggests that
the PM does not affect the establishment of the primordial
follicle pool, does not block a particular stage of follicle
development and does not lead to increased follicular re-
cruitment. The fact that both follicles that depend on
ovarian intrinsic factors and those that depend on the in-
put of extrinsic factors are affected suggests that the prob-
lem may be intrinsic to the ovary.
Premutation leads to granulosa cell abnormalities
GCs are key to the functioning of the follicle. The
CGGnih mice had fewer GCs in the antral follicles than
did the WT mice. Furthermore, there were significantly
more antral follicles in which the GC layer was detached
and the corona was partial or missing in both the
CGGnih and YAC-TG296 models. Signs of atresia were
also increased. In the CGGnih mice, there was a high ra-
tio of atretic follicles to advancing follicles, irrespective
of estrus cycle stage. Using terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) to analyze
ovarian sections at PD35, 16 weeks and 22 weeks, the
YAC-TG296 mice were seen to have increased numbers
of antral follicles that appeared atretic compared with
the WT mice. Thus the PM could lead to increased apop-
tosis in the ovaries.
Premutation leads to subfertility
Features of fertility were investigated for the YAC-TG296
mice. These mice had an increased frequency of sterility,
and, among those that were fertile, reduced litter sizes and
were older in having their first litter. At 9 to 22 weeks,
these mice had higher follicle stimulating hormone and
lower luteinizing hormone levels compared with WT
mice. They also had higher levels of 17β-E2 at 10 to 12weeks, although these levels normalized to those of WT
mice at 16 to 22 weeks.
Premutation leads to altered gene expression
Expression of genes known to be involved in ovarian
function was investigated for YAC-TG296 mouse ovaries
at two stages: PD25 and proestrus-stage adults (8 to 14
weeks). The LH receptor (Lhr) was significantly down-
regulated at both stages. However, no differences in
mRNA levels were found between PM and WT mice,
among other major known regulators and markers of
folliculogenesis. LH-induced ovulation-related genes were
further investigated and found to be downregulated, spe-
cifically at the proestrus stage in adults. These findings
suggest that the LH-mediated pathway could be affected
in PM ovaries. The PI3K-Akt pathway, a pathway known
to play a critical role in gonadotropin-mediated GC differ-
entiation, cumulus expansion and oocyte maturation, was
also investigated. YAC-TG296 mouse ovaries had a signifi-
cant reduction in the levels of phosphorylated Akt, but
not total Akt. Given the interaction between the Akt and
mTOR pathways, the status of mTOR was also investi-
gated. Again, there was a reduction in the levels of the
phosphorylated mTOR protein but not total mTOR.
Thus, the Akt-mTOR-mediated signaling cascade may be
altered in PM ovaries. A role for reduced mTOR phos-
phorylation in FXTAS is suggested by the observation that
activating mTOR ameliorates neurodegeneration in a fly
model of FXTAS [44]. It will be of interest to see whether
this activation improves ovarian function in flies and
mouse models.
Ovarian phenotype altered in knockout model
An interesting ovarian phenotype has been observed in
the full mutation knockout (KO) mouse model [35]. By
3 weeks, homozygous KO mice had an increased num-
ber of follicles compared with WT mice. By 18 weeks,
the size of the ovaries in the KO mice was larger than
those in the WT mice and showed prominent cysts, con-
sistent with corpus lutea development. Lysates from 9-
to-18-week-old ovaries showed increased protein levels
of Tsc2, Sash1 and mTOR. The authors suggested that
increased levels of these proteins seen in the absence of
FMRP, may lead to precocious follicular development.
Thus, this KO model may have the potential to model
ovarian insufficiency; however whether the related me-
chanism is associated with FXPOI is an open question.
Women who carry the full mutation do not show signs
of POI. Whether this is due to the fact that they are het-
erozygous for the loss of FMRP is unknown.
Fly model: effect of modifying genes and more
In Drosophila ovaries, a small population of germ-
line stem cells (GSCs) is maintained in a well-defined
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for investigating the regulatory mechanisms that deter-
mine the fate of stem cells [45,46]. A typical Drosophila
ovary is composed of 16 to 20 ovarioles. Each ovariole
consists of an anterior functional unit called a germarium
that houses GSCs and somatic lineages, and a linear string
of differentiated egg chambers posterior to the germarium.
The tip of the germarium consists of specialized cells that
maintain the microenvironments called niches and these
are essential for GSC proliferation and maintenance. At
this tip, GSCs normally divide asymmetrically to ensure
that one daughter cell remains attached to the niche cells
for self-renewal, while the other is displaced from the
niche, becoming a cystoblast, which initiates differenti-
ation and sustains oogenesis [47]. Studies from multiple
laboratories have identified the genes that are essential for
GSC fate determination [48,49].
Drosophila GSCs have been used as a model to show
that FMRP can modulate the fate of stem cells: Yang
et al. [50] found that dFmr1 is required for both main-
taining GSCs and repressing differentiation. Very re-
cently, transgenic lines have been developed that drive
the expression of the PM rCGG repeat in fly ovaries and
these rCGGs were found to be toxic in the germ line as
well (PJ, unpublished data). These results suggest that
both the reduction of FMRP and expression of PM
rCGG repeats could have detrimental effects on fly ovary
and stem cell maintenance.
Because of the relative ease of model construction
compared with other model systems, two other import-
ant questions can be addressed at relatively low cost.
First, the fly model can be used to test the effect of gen-
etic modifiers on the ovarian phenotype. This could be
valuable not only for our understanding of the pathoge-
nic mechanism, but may also shed light on genes whose
human homologs may contribute to the variable pene-
trance of FXPOI. Second, the Drosophila model has sig-
nificant potential for increasing our understanding of
the non-linear effect of repeat number by creating con-
structs that vary only by repeat number.
Non-human primate model: bridging the translational gap
Many genetic, cellular and physiological differences exist
between the current model systems used for studying
FXPOI and human females. Non-human primates (NHPs)
offer a clinically relevant model system in which to ex-
plore the molecular mechanisms of the PM on ovarian
function. One of the limitations in modeling FXPOI is that
there are no known naturally occurring animal models
with FMR1 repeat mutations, including NHPs [51,52]. Of
the species tested thus far, only NHPs have CGG repeat
numbers comparable to those in humans [53]. The repeat
sequence found in the great apes (Hominidae) shows
striking similarity to that in humans, with CGG repeatlengths ranging from 20 to 39 interrupted by 1 to 6 AGG
interruptions and the longest and most variable CGG
lengths at the 3' end of the repeat [53,54].
While it is possible that spontaneous CGG repeat ex-
pansion to the pre- and full mutation range does occur
in NHP populations, screening would be expensive and
unlikely to yield sufficient animal numbers for meaning-
ful studies. Instead efforts are currently underway at the
Washington National Primate Research Center to gener-
ate a NHP transgenic model of FXPOI. Using technolo-
gies based on embryonic stem cells, Dr Curnow’s team
aims to introduce the human PM sequence into the
macaque endogenous FMR1 gene and generate NHP fe-
males with germ-line expression of the PM. While em-
bryonic stem cells from species other than the mouse
have been historically less amenable to gene-targeting
strategies, recent work on the rat, human and marmoset
has shown transgene efficiencies and stability equivalent
to the mouse following the refinement of the culture
conditions for embryonic stem cells and gene-targeting
methods [55-62]. Full-scale development of a NHP mo-
del of FXPOI necessitates a long-term approach with the
generation of a self-sufficient breeding colony of FXPOI-
affected females in which reproductive function related
specifically to FXPOI can be studied. These studies can
be done in conjunction with other pertinent aspects of
fragile X-associated disorders.
Induced pluripotent stem cell model: examination of
affected tissues
Findings from the PM mouse models noted above sug-
gest that GC function is involved in the cellular cause of
FXPOI, as is true for other forms of POI [63-65]. It is
difficult to study GC function in women, as the proced-
ure to obtain follicles with GCs is quite invasive and,
thus, patient material is scarce. Patient-specific induced
pluripotent stem cells (iPSCs) derived from adult som-
atic cells and which have differentiated into GC-like cells
represent one novel possible option for generating an
abundance of material for research purposes without
any invasive procedures.
Work by Kang et al. has shown the ability of mouse
iPSCs to differentiate into GC-like cells that express
FSHR and secrete estradiol after co-culture with mouse
GCs isolated from stimulated follicles [64]. However, this
research has not been extended to human iPSCs. Adapt-
ing this protocol would enable researchers to investigate
repeat length instability, cellular and signaling defects
and cell viability in in vitro GCs derived from patient-
specific human iPSCs. These types of in vitro studies
could elucidate novel defects in somatic cells that support
follicle survival and maturation that contribute to POI.
Recently, Hayashi et al. showed that functional oocytes
could be derived from mouse iPSCs [66]. While this
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normal mouse GCs transplanted under the ovarian bursa,
the technique showed the feasibility of reconstituting a
follicle and generating a functional oocyte from mouse
iPSCs. If this system could be adapted to human female
iPSCs using a wholly in vitro methodology in combination
with a GC differentiation protocol, researchers could
study how signaling defects in GCs contribute to oocyte
death in POI. For treatment of infertility related to POI,
patient-specific iPSCs could be differentiated into func-
tional oocytes with GCs from non-POI patients to allow
POI women to produce their own genetic offspring. Al-
though these types of experiments and clinical implica-
tions are years away from being realized, human POI iPSC
studies are a novel way for furthering understanding of
FXPOI and its consequences.
Possible mechanisms of FXPOI: what have we learned
from model systems?
As emphasized above, we know little about the disease
pathology underlying FXPOI. A number of lines of evi-
dence suggest that the pathology is not related to an
FMRP deficit. Firstly, FXPOI is seen in women who have
repeat numbers that are not associated with an FMRP
deficit, at least in peripheral blood. Secondly, women
who carry the completely silenced full mutation, and
thus do not express FMRP in, on average, half their cells,
do not show symptoms of FXPOI. Thirdly, the YAC-
TG296 mouse model is homozygous for the WT Fmr1
allele, yet shows signs of ovarian dysfunction. Thus
FXPOI, like FXTAS, is not likely to be the result of the
loss of FMRP. However, how this relates to the observa-
tion that Fmr1 KO mice also show ovarian dysfunction
is unclear.
In terms of the molecular mechanism, there may be
parallels to FXTAS. Work with tissue cultures has shown
that expression of mRNA from the PM allele is deleteri-
ous to a wide variety of cell types; thus it is reasonable
to think that FXTAS and FXPOI may share a common
pathological basis. A variety of models have been pro-
posed to explain the pathology of FXTAS and support
for these comes from various model systems. The RNA
gain-of-function model predicts that the long rCGG
track sequesters specific CGG-binding proteins, result-
ing in the loss of normal cell function. Various proteins
have been identified that directly bind to CGG-RNA and
whose sequestration may affect cell viability, including:
hnRNP A2/B1, a protein involved in pre-mRNA process-
ing [67,68]; Pur α, a protein that has been implicated in
transcription regulation and neuronal development [67];
and the miRNA-processing complex, DROSHA-DGCR8
[69]. These proteins in turn are able to recruit additional
proteins like CUGBP1 in the case of hnRNP A2/B1 [70]
and the RNA helicase, Rm62, in the case of Purα/DDX5[71]. Overexpression of DROSHA [69], hnRNP A2/B1,
CUGBP1 [72], Pur α [67] and Rm62 [71] rescue neuro-
degeneration in a fly model of FXTAS, but whether they
rescue the mammalian phenotype remains to be seen.
Transcripts from the FMR1 locus may be deleterious
in other ways. For example, the rCGG forms stable
secondary structures including hairpins [73,74], which
are substrates for the human enzyme Dicer [74]. Dicer
is responsible for generating small RNAs that can
act via the RNA interference pathway to reduce post-
transcriptionally the expression of genes containing simi-
lar repeat tracts. Expression of RNA with 80 CAG repeats,
which also forms hairpins, generates Dicer-dependent
small RNAs that are toxic to neuronal cells in culture [75].
It remains to be seen whether rCGGs could be toxic in
similar ways.
Various antisense transcripts are also made from the
human FMR1 gene and these potentially contribute to
disease pathology in different ways. While the expression
of some of these transcripts is low in normal cells, in
PM carriers some of these transcripts are present at
levels comparable to that of the sense transcript [76].
Some double-stranded RNAs, including rCUG.rCAG,
can activate the innate immune response in Drosophila
in a Dicer-dependent manner [75]. Such double-stranded
RNAs could be generated via the annealing of sense and
antisense transcripts produced from the FMR1 gene. The
antisense rCGGs may also sequester proteins, as proposed
for the sense transcript. Furthermore, since the repeat is
located in a putative open reading frame on some of the
antisense transcripts, it could produce a repeat-containing
protein, in this case a polyproline-containing protein,
which could contribute to disease pathology [76].
Another protein-based model arises from the observa-
tion that repeated sequences can increase the frequency
at which translation initiates at non-ATG codons, a
process known as repeat-associated non-ATG (RAN)
translation [77]. In humans, and in mice and flies con-
taining the human 5' UTR, there is evidence to suggest
that such start sites are used to make polyglycine and/or
polyalanine-containing proteins that are neurotoxic [78].
Such proteins can be detected in the brains of individ-
uals with FXTAS.
The YAC-TG296 and the CGGdut mouse models do
have the human FMR1 5' UTR upstream of the repeat
and thus can make the polyglycine and polyalanine pro-
teins. In contrast, the CGGnih mouse retains the murine
5' UTR and thus has a stop codon immediately upstream
of the repeat. The fact that the CGGnih mouse does ex-
hibit signs of ovarian dysfunction suggests that at least
some pathology may arise independently of RAN trans-
lation. However, the relative contribution of RNA-based
pathology and protein-based pathology to the overall phe-
notype remains to be determined.
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are associated with the formation of intranuclear inclu-
sions in patients, in cells in tissue culture as well as in
the brains of mice and fly models. While intranuclear in-
clusions in the brain are a hallmark of FXTAS, very few
inclusions are seen in the ovaries of PM mouse models
and humans. More data are necessary to establish defini-
tively whether inclusions are a feature of FXPOI. The
few inclusions noted in stromal cells of grossly normal
appearing ovaries from humans [79] may suggest an un-
derlying toxic gain-of-function related to protein degrad-
ation. The absence of inclusions in follicles may be the
result of the rapid loss of affected follicles, too fast for
inclusions to be observed [79]. This would be similar to
that seen in Purkinje cells in FXTAS [80]. However, it is
unclear whether intranuclear inclusions are protective,
pathogenic or neutral markers of disease pathology.
Lastly, more work needs to focus on altered gene ex-
pression in PM models. Data from the YAC-TG296 model
shows reduced expression of phosphorylated Akt and
mTOR, while the KO model showed elevated mTOR
levels. mTOR dysregulation in these animals is of interest
since both underexpression and overexpression of mTOR
[81,82] can result in ovarian dysfunction. It has been
shown that mTOR inhibition results in reduced GC pro-
liferation [83], a significant phenotype in the PM mouse
models. We speculate that a role for reduced mTOR
phosphorylation in FXPOI could also account for the
non-linear relation between CGG repeat number and the
risk of FXPOI. As the repeat number increases, FMRP
levels are predicted to decrease, because of the difficulties
associated with the translation of large PM alleles. This
decrease in FMRP could in turn lead to increased levels of
mTOR phosphorylation, which could offset the loss of
mTOR resulting from the consequences of expression
of the PM rCGGs. However, whether mTOR dysregu-
lation is the proximal cause of the ovarian dysfunc-
tion seen in FXPOI still remains to be determined
and studies to address mTOR levels in human female
PM carriers are sorely needed. Also, some phenotype
differences observed between models may be related
to the different background strains. Although this can
complicate comparisons, it also points to the import-
ance of modifying genes to explain the variable pres-
entation of FXPOI.
Conclusions
Clearly, the value of model systems in determining the
underlying cause of FXPOI cannot be overstated. Each
system has its advantages. The fly model will be valuable
for determining the non-linear effect of increasing repeat
number on the ovary in a cost-efficient way. It will also
be the model of choice for identifying modifier genes
using effective genetic screens. As always, caution mustbe taken in ascribing phenotype outcomes in the fly to
mammals. In particular, the development and aging pro-
cesses occurring within ovaries differ between the fly
model and mammalian systems. Thus, disease progres-
sion and histological studies of FXPOI will need to be
studied in mammalian models. Already rodent models
have shown their potential and will continue to help in
elucidating mechanisms and identifying potential treat-
ments. Still, the genetic, cellular and physiological differ-
ences between current vertebrate model systems and
humans suggest that additional model systems should be
developed and tested in parallel to expedite translational
research efforts. The translational bridge between cur-
rent animal models and humans can best be met by NHP
studies. Finally, patient-specific iPSCs derived from adult
somatic cells and differentiated into GC-like cells repre-
sent a viable option for generating material needed for re-
search without invasive procedures that minimizes the
excessive use of animals. Thus, the combined use of mo-
del systems promises to elucidate the underlying mecha-
nisms of FXPOI and the associated risk factors.
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